<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wang Z</submitter><funding>Ministry of Science and Technology of the People&amp;apos;s Republic of China</funding><pagination>20653-20663</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7439698</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>5(32)</volume><pubmed_abstract>Clinically diagnosing low-grade gliomas and microscopic metastatic tumors in the spinal cord using magnetic resonance imaging (MRI) is challenging, as the blood-brain barrier (BBB) almost completely excludes the MRI contrast agent gadopentetate dimeglumine, GdDTPA (Magnevist), from the brain. The development of a more efficient, safe, and broad-spectrum glioma diagnosis and treatment would therefore have a great clinical value. Based on the high expression levels of both transferrin receptor 1 (TfR1) and low-density lipoprotein receptor-related protein 1 (LRP1) in BBB-related cells and glioma cells, we designed a novel protein nanoparticle, ferritin-HREV107-Angiopep-2 (Fn-Rev-Ang). We found that Fn-Rev-Ang rapidly crossed the BBB in mice and had drug-loading properties. Moreover, the brain</pubmed_abstract><journal>ACS omega</journal><pubmed_title>Development of a Novel Dual-Order Protein-Based Nanodelivery Carrier That Rapidly Targets Low-Grade Gliomas with Microscopic Metastasis &lt;i>in Vivo&lt;/i>.</pubmed_title><pmcid>PMC7439698</pmcid><funding_grant_id>2018ZX09711003</funding_grant_id><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Zhong W</pubmed_authors><pubmed_authors>Lin J</pubmed_authors><pubmed_authors>Tian N</pubmed_authors><pubmed_authors>Wang Z</pubmed_authors><pubmed_authors>Zhou X</pubmed_authors><pubmed_authors>Fan S</pubmed_authors><pubmed_authors>Xu Y</pubmed_authors><pubmed_authors>Sheng F</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of a Novel Dual-Order Protein-Based Nanodelivery Carrier That Rapidly Targets Low-Grade Gliomas with Microscopic Metastasis &lt;i>in Vivo&lt;/i>.</name><description>Clinically diagnosing low-grade gliomas and microscopic metastatic tumors in the spinal cord using magnetic resonance imaging (MRI) is challenging, as the blood-brain barrier (BBB) almost completely excludes the MRI contrast agent gadopentetate dimeglumine, GdDTPA (Magnevist), from the brain. The development of a more efficient, safe, and broad-spectrum glioma diagnosis and treatment would therefore have a great clinical value. Based on the high expression levels of both transferrin receptor 1 (TfR1) and low-density lipoprotein receptor-related protein 1 (LRP1) in BBB-related cells and glioma cells, we designed a novel protein nanoparticle, ferritin-HREV107-Angiopep-2 (Fn-Rev-Ang). We found that Fn-Rev-Ang rapidly crossed the BBB in mice and had drug-loading properties. Moreover, the brain</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Aug</publication><modification>2026-05-08T13:38:28.001Z</modification><creation>2025-06-01T02:32:42.917Z</creation></dates><accession>S-EPMC7439698</accession><cross_references><pubmed>32832819</pubmed><doi>10.1021/acsomega.0c03073</doi></cross_references></HashMap>